New insights on pharmacological and therapeutic potentials of trimetazidine beyond anti-anginal drug: A comprehensive review

Eur J Pharmacol. 2024 Dec 15:985:177062. doi: 10.1016/j.ejphar.2024.177062. Epub 2024 Oct 19.

Abstract

Trimetazidine (TMZ) is a beneficial and well-tolerable anti-anginal drug which has protective action towards ischemia and reperfusion injury. TMZ performs its anti-ischemic effect by modifying cardiac metabolism without shifting the hemodynamic functions, so it represents an outstanding complementary perspective to the general angina treatment. TMZ possesses a positive impact on the inflammatory profile, and also endothelial function furthermore displays various benefits through minimising the number, as well as the intensity of angina strikes and ameliorating the clinical indication and symptoms of myocardium ischemia. It is administrated as monotherapy along with a combination of different antianginal drugs. Apart from anti-angina action, in recent years TMZ has shown various pharmacological activities such as neuroprotective, renal protective, hepato-protective, cardio-protective effects, and other beneficial pharmacological activities. We select to write the present review article to cover the different pharmacological and therapeutic potentials of TMZ.

Keywords: Anticancer; Cardioprotective; Hepatoprotective; Neuroprotective; Renal protective.

Publication types

  • Review

MeSH terms

  • Angina Pectoris / drug therapy
  • Animals
  • Cardiotonic Agents / pharmacology
  • Cardiotonic Agents / therapeutic use
  • Humans
  • Trimetazidine* / pharmacology
  • Trimetazidine* / therapeutic use
  • Vasodilator Agents / pharmacology
  • Vasodilator Agents / therapeutic use

Substances

  • Trimetazidine
  • Vasodilator Agents
  • Cardiotonic Agents